Journal of Hematology & Oncology, Год журнала: 2022, Номер 15(1)

Опубликована: Сен. 12, 2022

Abstract Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and cells (CTCs) can be isolated from the blood other body fluids. This review will focus on current technologies clinical applications liquid biopsies. ctDNA/cfDNA has been analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), personalized by (CAPP-Seq), whole genome bisulfite (WGBS-Seq), exome (WES), (WGS). CTCs have biomarker-based cell capture, positive or negative enrichment based biophysical properties. being exploited in variety of applications: differentiating unique immune checkpoint blockade response patterns serial samples; predicting baseline biopsy characteristics; resistance to targeted therapy chemotherapy as well immunotherapy, including CAR-T cells, sampling; assessing shed multiple metastatic sites; potentially actionable alterations; analyzing prognosis burden, after surgery; interrogating difficult-to tumors; detecting at early stages. The latter limited small amounts tumor-derived components into circulation; furthermore, cfDNA assessment all cancers confounded clonal hematopoeisis indeterminate potential, especially elderly. technically more difficult isolate cfDNA, but permit functional assays, evaluation CTC-derived DNA, RNA proteins, single-cell analysis. Blood less invasive than tissue hence amenable collection, which provide critical information real time. In conclusion, is powerful tool, remarkable advances this technology impacted aspects oncology, diagnosis management refractory disease. Future research may fluids beyond blood, such ascites, effusions, urine, cerebrospinal fluid, methylation elements exosomes.

Язык: Английский